HIMS_OUT_1 [2025-04-29 09:43:26 -0400] 4633 Bytes | 1398 tokens | Cum: 1398 tkns (17.47% of 8k)
==========================================================================

Much activity, there is. Hims & Hers (HIMS), lifted from $28.48 to $36.13, it has. 9:43 AM on Tue Apr 29, 2025, it is. Wise we must be, quick we must act. Hmmm.

--- COMPANY PROFILE ---
Company: Hims & Hers (HIMS)
IPO: 2021-01-21 (4 Years Ago)
Market Cap: $6,551,662,718
Shares Outstanding: 213,790,000
Industry: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE
Exchange: XNYS
Description: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Here’s a list of headlines for Hims & Hers:

Today 08:12AM - Bet on Winning DuPont Analysis & Pick 3 Top Stocks
07:30AM - Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
Apr-28-25 05:17PM - Hims & Hers: Selling Options On This High-Growth Gem Could Yield 20% Or More (Rating Upgrade)
Apr-28-25 05:17PM 01:26PM - EMEA Growth & Product Launches to Support Boston Scientific Stock
Apr-28-25 05:17PM 11:22AM - Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
Apr-28-25 05:17PM 10:00AM - Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
Apr-28-25 05:17PM 09:19AM - HSIC Gears Up for Q1 Earnings: Here's What You Need to Know
Apr-28-25 05:17PM 09:12AM - Here's How Charles River is Placed Just Ahead of Q1 Earnings
Apr-28-25 05:17PM 08:45AM - GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
Apr-25-25 05:45PM - Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Apr-25-25 05:45PM 02:45PM - Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last
Apr-24-25 11:39AM - EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
Apr-23-25 11:21AM - Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy
Apr-23-25 11:21AM 07:38AM - BUZZ Investing: Tariff Chaos Shakes U.S. Equities
Apr-23-25 11:21AM 05:04AM - 2 Reasons to Like HIMS and 1 to Stay Skeptical
Apr-22-25 09:00AM - Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Apr-22-25 09:00AM 08:39AM - Zacks Industry Outlook Highlights Veeva Systems, Hims & Hers Health and Butterfly Network
Apr-22-25 09:00AM 08:13AM - Zimmer Biomet to Report Q1 Earnings: Here's What to Expect
Apr-22-25 09:00AM 07:29AM - Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
Apr-21-25 05:32PM - Is Hims & Hers Health, Inc. (HIMS) the Best Telehealth Stock to Buy Now?
Apr-21-25 05:32PM 12:35PM - Hims & Hers: Top Pick For The Next Decade
Apr-21-25 05:32PM 09:57AM - Will Robust Exome and Genome Growth Boost WGS' Q1 Earnings Results?

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-29T10:23:00Z - Can Shiba Inu Reach $1 in 2030?
B2 - 2025-04-02T22:18:49Z - Why Hims & Hers Health Stock Couldn't Beat the Market Today
B3 - 2025-04-02T16:14:00Z - 3 Stocks Leading Healthcare’s Comeback as Wall Street Turns Defensive
B4 - 2025-03-29T12:15:00Z - Is Hims & Hers Stock Too Cheap to Pass Up?
B5 - 2025-03-18T15:40:34Z - Why Hims & Hers Stock Tumbled on Tuesday
B6 - 2025-03-10T14:15:00Z - 3 Cold Stocks That Can Bounce Back This Week

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Hims & Hers (HIMS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

HIMS_OUT_3 [2025-04-29 09:43:27 -0400] 877 Bytes | 223 tokens | Cum: 1623 tkns (20.29% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Why Hims & Hers Health Stock Couldn't Beat the Market Today**Date: Unknown DateSource: Unknown SourceURL: https://www.fool.com/investing/2025/04/02/why-hims-hers-health-stock-couldnt-beat-the-market/?source=iedfolrf0000001Hims & Hers Health stock struggled to outperform the S&P 500 index on Wednesday, despite the company's announcement of new obesity drug offerings. Analyst Jailendra Singh of Truist Securities reiterated a 'hold' recommendation on the stock, noting that much of the initial excitement was due to an erroneous assumption about the company's arrangement with Eli Lilly.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HIMS_OUT_5 [2025-04-29 09:43:28 -0400] 902 Bytes | 271 tokens | Cum: 1896 tkns (23.70% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-29T13:17:48Z - Him & Hers, Novo Nordisk Partner To Sell Heavily Discounted Wegovy...
A2 - 2025-04-29T12:38:59Z - Stocks making the biggest moves premarket: Spotify, Hims & Hers, Sherwin-Williams and more - RocketN...
A3 - 2025-04-29T12:50:06Z - Daily Game Plan - Opening Print...
A4 - 2025-04-29T13:00:00Z - Humana's CenterWell Expands Specialty Pharmacy As GLP-1 Drugs Take Off...
A5 - 2025-04-29T12:57:20Z - Hims & Hers geht Partnerschaft mit Novo Nordisk ein, um Wegovy auf seiner Plattform zu verkaufen...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

HIMS_OUT_7 [2025-04-29 09:43:29 -0400] 1181 Bytes | 307 tokens | Cum: 2205 tkns (27.56% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Him & Hers, Novo Nordisk Partner To Sell Heavily Discounted Wegovy**Date: 2025-04-29Source: {'uri': 'zerohedge.com', 'dataType': 'news', 'title': 'Zero Hedge'}URL: https://www.zerohedge.com/medical/him-hers-novo-nordisk-partner-sell-heavily-discounted-wegovyNovo Nordisk is teaming up with major telehealth companies to sell its blockbuster weight-loss drug Wegovy directly to U.S. consumers at a steep discount through its new direct-to-consumer pharmacy platform. For many, the monthly cost of Wegovy will now be more affordable than the average monthly payment for a new vehicle.

Bloomberg reported that NovoCare will begin offering Wegovy through telehealth firms Hims & Hers Health, LifeMD, and Ro. The weight-loss drug will be offered as subscription models on Hims and Ro. Hims will sell Wegovy for $599 monthly, including a membership offering clinical and nutritional support. Ro will

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HIMS_OUT_9 [2025-04-29 09:43:30 -0400] 1181 Bytes | 274 tokens | Cum: 2481 tkns (31.01% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): charge $499 monthly for Wegovy, plus a $145 membership fee after the first month. Both of these monthly prices are being offered at more than 50% of the drug's retail price in the U.S. market.

"The strategy comes as rival Eli Lilly & Co. has teamed up with telehealth firms like Ro to distribute lower-cost vials of its own obesity medication, Zepbound. Lilly doesn't have a similar partnership with Hims, which sells Zepbound independently at a premium compared to Lilly's discounted offering," Bloomberg noted.

We noted in early March that Novo was preparing for a direct-to-consumer launch to take on Lilly's Zepbound.

Andrew Dudum, CEO and founder of Hims, said Novo's new partnership is "delivering the future of healthcare" by offering Americans affordable, breakthrough medicine that improves long-term health outcomes.

"Beyond this initial collaboration, the companies are developing a r

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HIMS_OUT_11 [2025-04-29 09:43:31 -0400] 1181 Bytes | 282 tokens | Cum: 2765 tkns (34.56% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): oadmap that combines Novo Nordisk's innovative medications with Hims' ability to deliver access to quality care at scale, with the goal of improving long-term outcomes for more people living with chronic disease, and doing that more affordably," said Dave Moore, Novo's executive vice president for U.S. operations.

Last year, elevated demand for Wegovy and Zepbound led telehealth companies -- including Hims and Ro -- to sell compounded versions of these wonder drugs at steep discounts.

Moore told Bloomberg that more affordable pricing and increased partnerships are a "change" for Wegovy and that "this is different than where we have been in the last couple of years."

In markets, shares of Hims in New York surged as much as 30% in premarket trading. On the year, shares are up nearly 18% as of Monday's close.

The short interest in Hims recently touched 34.33% of the float, or about 61 m

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HIMS_OUT_13 [2025-04-29 09:43:32 -0400] 303 Bytes | 88 tokens | Cum: 2855 tkns (35.69% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): illion shares short.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HIMS_OUT_15 [2025-04-29 09:43:34 -0400] 238 Bytes | 59 tokens | Cum: 2916 tkns (36.45% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HIMS_OUT_17 [2025-04-29 09:43:34 -0400] 251 Bytes | 78 tokens | Cum: 2997 tkns (37.46% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

HIMS_OUT_19 [2025-04-29 09:43:40 -0400] 14123 Bytes | 3892 tokens | Cum: 6892 tkns (86.15% of 8k)
==========================================================================

This is our set of metrics for Hims & Hers.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-----------------------+
| Volume: 0 | Perf Month: -10.78% | Option/Short: Yes / Yes | Sales Y/Y TTM: 69.33% |
+--------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 25.79M | Perf Quarter: -6.65% | Short Float: 33.31% | ROE: 30.71% |
+--------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 0.00 | Index: RUT | Short Ratio: 2.35 | ROI: 25.92% |
+--------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 46.98 | Market Cap: 6.33B | Short Interest: 60.66M | Sales Surprise: 2.18% |
+--------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 3.08 | Shs Outstand: 212.46M | Beta: 1.87 | EPS Surprise: 1.57% |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 2.12% | Shs Float: 182.08M | Sales Q/Q: 95.09% | P/E: 53.25 |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -19.88% | Inst Own: 74.22% | Sales past 5Y: 62.28% | Earnings: May 05 AMC |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA200: 6.60% | Insider Own: 18.04% | Employees: 1637 | |
+--------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 10.22% | Insider Trans: -6.35% | Debt/Eq: 0.02 | |
+--------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Hims & Hers officers or majority shareholders (if available).

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Becklund Irene (PAO) on 2025-04-22
- Class A Common Stock: 2936 shares at $26.49 (D) Footnote: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 7, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Baird Melissa (Chief Operating Officer) on 2025-04-21
- Class A Common Stock: 22568 shares at $1.75 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Class A Common Stock: 10765 shares at $2.43 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Class A Common Stock: 27035 shares at $25.6587 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Class A Common Stock: 6298 shares at $26.2898 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Stock Option (right to buy): 22568 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Stock Option (right to buy): 10765 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Dudum Andrew (Chief Executive Officer) on 2025-04-16
- Class A Common Stock: 17001 shares at $2.43 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- Class A Common Stock: 16667 shares at $2.43 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- Class A Common Stock: 33668 shares at $28.0213 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- Class A Common Stock: 2792 shares at $28.3066 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- Class A Common Stock: 47534 shares at $28.2344 (I) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- Stock Option (right to buy): 17001 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- Stock Option (right to buy): 16667 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Okupe Oluyemi (Chief Financial Officer) on 2025-04-15
- Class A Common Stock: 1400 shares at $11.53 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.
- Class A Common Stock: 5037 shares at $5.01 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.
- Class A Common Stock: 11581 shares at $28.502 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.
- Stock Option (right to buy): 1400 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.
- Stock Option (right to buy): 5037 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Boughton Soleil (Chief Legal Officer) on 2025-03-03
- Class A Common Stock: 4151 shares at $45.14 (D) Footnote: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.
- Class A Common Stock: 3236 shares at $28.72 (D) Footnote: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Baird Melissa (Chief Operating Officer) on 2025-04-09
- Class A Common Stock: 33337 shares at $1.75 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Class A Common Stock: 10199 shares at $25.8234 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Class A Common Stock: 11735 shares at $26.936 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Class A Common Stock: 3011 shares at $28.5479 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Class A Common Stock: 8392 shares at $29.2258 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.
- Stock Option (right to buy): 33337 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Baird Melissa (Chief Operating Officer) on 2025-04-04
- Class A Common Stock: 40380 shares at $5.01 (D)
- Stock Option (right to buy): 40380 shares at $0 (D)

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Okupe Oluyemi (Chief Financial Officer) on 2025-04-02
- Class A Common Stock: 6437 shares at $5.01 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.
- Class A Common Stock: 11581 shares at $29.2577 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.
- Stock Option (right to buy): 6437 shares at $0 (D) Footnote: The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Becklund Irene (PAO) on 2025-04-03
- Class A Common Stock: 2203 shares at $28.78 (D) Footnote: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 7, 2024 by the Reporting Person.

Inside Trans: Hims & Hers Health, Inc. (HIMS) by Baird Melissa (Chief Operating Officer) on 2025-03-31
- Class A Common Stock: 13460 shares at $5.01 (D)
- Stock Option (right to buy): 13460 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1476514000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 126038000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 36.43
Average Volume: 23208821.48
30-Day High: 36.43
30-Day Low: 25.35

[Detailed Financials: TTM 2024]
- Total Assets: $707,539,000.00
- Total Liabilities: $230,823,000.00
- Total Equity: $476,716,000.00
- Current Assets: $395,831,000.00
- Current Liabilities: $221,367,000.00

[Income Statement: TTM 2024]
- Revenue: $1,476,514,000.00
- Net Income: $126,038,000.00
- Gross Profit: $1,173,135,000.00
- Operating Income: $61,903,000.00
- Earnings Per Share (EPS): 0.58

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $123,921,000.00

[Detailed Financials: FY 2024]
- Total Assets: $707,539,000.00
- Total Liabilities: $230,823,000.00
- Total Equity: $476,716,000.00
- Current Assets: $395,831,000.00
- Current Liabilities: $221,367,000.00

[Income Statement: FY 2024]
- Revenue: $1,476,514,000.00
- Net Income: $126,038,000.00
- Gross Profit: $1,173,135,000.00
- Operating Income: $61,903,000.00
- Earnings Per Share (EPS): 0.58

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $123,921,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Hims & Hers (HIMS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Hims & Hers.

2) MARKET_SCORE[]
This conversation was initiated because HIMS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for HIMS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, HIMS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect HIMS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Hims & Hers.

11) ETHICAL_RATING[]
Rate Hims & Hers’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Hims & Hers.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

HIMS_IN_21 [2025-04-29 09:43:41 -0400] 126 Bytes | 29 tokens | Cum: 7120 tkns (89.00% of 8k)
==========================================================================

====================================
[2025-04-29 09:43:41] # Analysis Completed
Elapsed Time: 16.08 seconds